John Lazarchick to Prospective Studies
This is a "connection" page, showing publications John Lazarchick has written about Prospective Studies.
Connection Strength
0.180
-
Characterization of Mast Cell Activation Syndrome. Am J Med Sci. 2017 03; 353(3):207-215.
Score: 0.084
-
Validation of the STA-Liatest DDi assay for exclusion of proximal deep vein thrombosis according to the latest Clinical and Laboratory Standards Institute/Food and Drug Administration guideline: results of a multicenter management study. Blood Coagul Fibrinolysis. 2018 Sep; 29(6):562-566.
Score: 0.024
-
Validation of STA-Liatest D-Di assay for exclusion of pulmonary embolism according to the latest Clinical and Laboratory Standard Institute/Food and Drug Administration guideline. Results of a multicenter management study. Blood Coagul Fibrinolysis. 2017 Apr; 28(3):254-260.
Score: 0.022
-
D-Dimer Use and Pulmonary Embolism Diagnosis in Emergency Units: Why Is There Such a Difference in Pulmonary Embolism Prevalence between the United States of America and Countries Outside USA? PLoS One. 2017; 12(1):e0169268.
Score: 0.021
-
Antenatal vitamin K therapy of the low-birth-weight infant. Am J Obstet Gynecol. 1994 Jan; 170(1 Pt 1):85-9.
Score: 0.017
-
Antithrombin alfa in hereditary antithrombin deficient patients: A phase 3 study of prophylactic intravenous administration in high risk situations. Thromb Haemost. 2008 Mar; 99(3):616-22.
Score: 0.011